Topics

Human medicines European public assessment report (EPAR): Xermelo, telotristat ethyl, Carcinoid Tumor,Neuroendocrine Tumors, Date of authorisation: 17/09/2017, Revision: 6, Status: Authorised

06:58 EDT 11 Oct 2019 | European Medicines Agency

Human medicines European public assessment report (EPAR): Xermelo, telotristat ethyl, Carcinoid Tumor,Neuroendocrine Tumors, Date of authorisation: 17/09/2017, Revision: 6, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): Xermelo, telotristat ethyl, Carcinoid Tumor,Neuroendocrine Tumors, Date of authorisation: 17/09/2017, Revision: 6, Status: Authorised

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Xermelo, telotristat ethyl, Carcinoid Tumor,Neuroendocrine Tumors, Date of authorisation: 17/09/2017, Revision: 6, Status: Authorised"

Quick Search